fluoxetine has been researched along with Cholera Infantum in 8 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine." | 5.14 | Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. ( Alpert, J; Baer, L; Bitran, S; Chuzi, S; Clain, AJ; Dording, C; Farabaugh, AH; Fava, M; McGrath, PJ; Mischoulon, D; Papakostas, GI; Witte, J, 2010) |
| "Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders." | 4.82 | Safety and side effect profile of fluoxetine. ( Wernicke, JF, 2004) |
| "Outpatients with recurrent unipolar depression (DSM-IV criteria; N = 1096) were randomly assigned in a 3:1 ratio to 10 weeks of treatment with venlafaxine ER or fluoxetine." | 2.73 | The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. ( Ahmed, S; Dunner, DL; Ferguson, JM; Friedman, ES; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kocsis, JH; Kornstein, SG; Musgnung, J; Nemeroff, CB; Ninan, PT; Pedersen, RD; Rothschild, AJ; Schatzberg, AF; Shelton, RC; Thase, ME; Trivedi, MH; Yan, B; Zajecka, JM, 2007) |
| "Depression has a female sex predilection with 2 to 3% of the pregnant women population presently requiring treatment with selective serotonin reuptake inhibitors (SSRI)." | 2.44 | Fetal and neonatal effects of maternal drug treatment for depression. ( Belik, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kowal-Bielecka, O | 1 |
| Fransen, J | 1 |
| Avouac, J | 1 |
| Becker, M | 1 |
| Kulak, A | 1 |
| Allanore, Y | 1 |
| Distler, O | 1 |
| Clements, P | 1 |
| Cutolo, M | 1 |
| Czirjak, L | 1 |
| Damjanov, N | 1 |
| Del Galdo, F | 1 |
| Denton, CP | 1 |
| Distler, JHW | 1 |
| Foeldvari, I | 1 |
| Figelstone, K | 1 |
| Frerix, M | 1 |
| Furst, DE | 1 |
| Guiducci, S | 1 |
| Hunzelmann, N | 1 |
| Khanna, D | 1 |
| Matucci-Cerinic, M | 1 |
| Herrick, AL | 1 |
| van den Hoogen, F | 1 |
| van Laar, JM | 1 |
| Riemekasten, G | 1 |
| Silver, R | 1 |
| Smith, V | 1 |
| Sulli, A | 1 |
| Tarner, I | 1 |
| Tyndall, A | 1 |
| Welling, J | 1 |
| Wigley, F | 1 |
| Valentini, G | 1 |
| Walker, UA | 1 |
| Zulian, F | 1 |
| Müller-Ladner, U | 1 |
| Belik, J | 1 |
| Farabaugh, AH | 1 |
| Bitran, S | 1 |
| Witte, J | 1 |
| Alpert, J | 1 |
| Chuzi, S | 1 |
| Clain, AJ | 1 |
| Baer, L | 1 |
| Fava, M | 2 |
| McGrath, PJ | 1 |
| Dording, C | 1 |
| Mischoulon, D | 1 |
| Papakostas, GI | 1 |
| Wernicke, JF | 1 |
| Keller, MB | 1 |
| Trivedi, MH | 1 |
| Thase, ME | 1 |
| Shelton, RC | 1 |
| Kornstein, SG | 2 |
| Nemeroff, CB | 1 |
| Friedman, ES | 1 |
| Gelenberg, AJ | 1 |
| Kocsis, JH | 1 |
| Dunner, DL | 2 |
| Hirschfeld, RM | 1 |
| Rothschild, AJ | 1 |
| Ferguson, JM | 1 |
| Schatzberg, AF | 1 |
| Zajecka, JM | 1 |
| Pedersen, RD | 1 |
| Yan, B | 1 |
| Ahmed, S | 1 |
| Musgnung, J | 1 |
| Ninan, PT | 1 |
| Amsterdam, JD | 1 |
| Deltito, JA | 1 |
| Salzman, C | 1 |
| Schwaller, M | 1 |
| Tenderich, G | 1 |
| Dagge, A | 1 |
| Schulz, U | 1 |
| Holzinger, J | 1 |
| Hornik, L | 1 |
| Mirow, N | 1 |
| Minami, K | 1 |
| Körfer, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study[NCT04300426] | Phase 2 | 75 participants (Actual) | Interventional | 2020-09-24 | Completed | ||
| "Effect of a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis on Oxygen Consumption, Functionality, and Quality of Life"[NCT06105073] | 67 participants (Anticipated) | Observational [Patient Registry] | 2022-03-01 | Recruiting | |||
| An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020] | Phase 4 | 1,096 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fluoxetine and Cholera Infantum
| Article | Year |
|---|---|
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Fetal and neonatal effects of maternal drug treatment for depression.
Topics: Animals; Depression; Female; Fetal Diseases; Fluoxetine; Gastrointestinal Diseases; Humans; Hyperten | 2008 |
Safety and side effect profile of fluoxetine.
Topics: Adolescent; Adult; Biotransformation; Bipolar Disorder; Cardiovascular Diseases; Child; Comorbidity; | 2004 |
Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Delayed-Ac | 2008 |
3 trials available for fluoxetine and Cholera Infantum
| Article | Year |
|---|---|
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder, Major; Female; Fluoxe | 2010 |
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depress | 2007 |
A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.
Topics: Adult; Ambulatory Care; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Fema | 1998 |
1 other study available for fluoxetine and Cholera Infantum
| Article | Year |
|---|---|
Successful use of cardiac allograft from serotonin antagonist intoxication.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Fluoxetine; Gastrointestinal Diseases; Heart Transplant | 2001 |